The EGFR/HER2 dual inhibitors, lapatinib and neratinib, which have similar half-maximal inhibitory concentration (IC50) values for EGFR and HER2, have been approved for patients with HER2-positive breast cancer (Table 2). Here, EGFR is linked to breast cancer.